Premium
Effect of phosphodiesterase type 5 inhibitors on prostate cancer risk and biochemical recurrence after prostate cancer treatment: A systematic review and meta‐analysis
Author(s) -
Wu Yougen,
Qu Xiaofeng,
Wang Yang,
Xia Ju,
Gu Yuting,
Qian Qingqing,
Hong Yang
Publication year - 2019
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/and.13198
Subject(s) - prostate cancer , medicine , meta analysis , oncology , cancer , biochemical recurrence , phosphodiesterase , cgmp specific phosphodiesterase type 5 , urology , gynecology , cancer research , enzyme , prostatectomy , biology , erectile dysfunction , biochemistry
Recent studies have examined the impact of phosphodiesterase type 5 inhibitors (PDE5‐Is) use on the risk of prostate cancer, and biochemical recurrence (BCR) in prostate cancer patients, but the results were inconsistent. A meta‐analysis was conducted to assess the associations with all published studies. Databases (PubMed, Web of Science and MEDLINE) were retrieved to identify relevant studies which explored the impact of PDE5‐Is use on the risk of prostate cancer, and BCR in prostate cancer patients. The summary results along with 95% confidence intervals (CIs) were calculated. Nine articles were eligible for the inclusion criteria. The pooled analysis showed that PDE5‐Is use was not related to the increased risk of prostate cancer (odds ratio (OR), 0.71; 95% CI, 0.40–1.29). Moreover, PDE5‐Is use was not linked to BCR risk in prostate cancer patients with erectile dysfunction (ED) following radical prostatectomy or radiation therapy (relative risk (RR), 1.09; 95% CI, 0.89–1.34). The heterogeneity test suggested moderate heterogeneity across studies. PDE5‐Is use does not influence the risk of prostate cancer, and BCR in prostate cancer patients. More well‐designed studies are warranted to confirm the findings of our analyses.